Topic: Immunotherapy

NHS patients in the UK have begun trials for a personalized mRNA vaccine designed to treat melanoma. The experimental treatment, which identifies proteins unique to an individual's tumor, is used in combination with other drugs and has shown a 49% reduction in the risk of death or recurrence over three years in early stages.

The shift in medical science toward mRNA-based therapeutic approaches is examined, specifically how these vaccines prime the immune system to attack cancer cells. Critics question the long-term efficacy and the definition of "vaccine" as the technology moves from preventative infectious disease measures to personalized cancer treatments.